Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS.
Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS.
复制标题
DOI：
10.1212/nxi.0000000000000093
复制
发表时间：
2015-06
期刊：
影响因子：
--
通讯作者：
Wraith DC
中科院分区：
文献类型：
--
作者：
Streeter HB;Rigden R;Martin KF;Scolding NJ;Wraith DC
The study was designed to test the efficacy of ATX-MS-1467 in a relevant preclinical model and to assess its safety for the treatment of patients with secondary progressive multiple sclerosis (SPMS). ATX-MS-1467 was tested for its ability to suppress experimental autoimmune encephalomyelitis (EAE) in the (Ob x DR2)F1 mouse both before and after disease onset. Safety was assessed by clinical assessment, MRI analysis, and the measurement of immune responses to self- and nonself-antigens in patients with SPMS. ATX-MS-1467 displayed a dose-dependent inhibition of EAE and was more effective than glatiramer acetate in the treatment of ongoing disease in humanized mice. A phase 1 open-label dose-escalating study demonstrated that ATX-MS-1467 was safe and well-tolerated in a group of 6 patients with SPMS, up to a dose of 800 µg. The results of this study support further development of ATX-MS-1467 in a clinical trial powered to investigate the immunologic and clinical benefits of treatment in relapsing-remitting MS. This study provides Class IV evidence that ATX-MS-1467 is safe and tolerated in a group of 6 patients with SPMS.
